Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 12

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 12
---
 to meet our future development goals. •The results of prior preclinical or clinical studies are not necessarily predictive of our future results. •The Clinical Studies of our Program Products’ have been and may in the future be conducted outside the United States, and the FDA or comparable foreign regulatory authorities may not accept data from such studies. •Our Program Products and the administration of our Program Products may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any. •Our business depends on the success of our Program Products, including obtaining regulatory approval to market our Product Candidates in the United States and/or other major foreign markets such as the European Union. •Even if we obtain regulatory approval for a product candidate, our products and business will remain subject to ongoing regulatory obligations and review. •Legislative or regulatory healthcare reforms in the United States or other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of our Program Products and to produce, market and distribute our Program Products after clearance or approval is obtained. •We face intense competition in an environment of rapid technological change and the possibility that our competitors may develop products and drug delivery systems that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our Program Products.

5 Risks Related to our Reliance on Third Parties •We rely on third parties to conduct certain elements of our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our Program Products. •We rely on third parties to manufacture the raw materials, including the active pharmaceutical ingredients that we use to create our therapeutic product candidate, and to manufacture the diagnostic devices, including the antibodies used for testing. Risks Related to Our Intellectual Property •If we are unable to obtain and maintain effective patent rights for our Product Candidates or any future product candidates, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or know -how, such proprietary information may be used by others to compete against us. •We may not be able to protect our intellectual property rights throughout the world. •We may not have sufficient patent lifespan to effectively protect our products and business. •If we are unable to maintain effective